A5038584853- Inflammatory Bowel Disease
- Microscopic Colitis
- Autoimmune and Inflammatory Disorders
- Pancreatitis Pathology and Treatment
- Helicobacter pylori-related gastroenterology studies
- Eosinophilic Esophagitis
- Diagnosis and treatment of tuberculosis
- Liver Diseases and Immunity
- Celiac Disease Research and Management
- Health Systems, Economic Evaluations, Quality of Life
- Pregnancy and Medication Impact
- Immunodeficiency and Autoimmune Disorders
- Reproductive System and Pregnancy
- Systemic Lupus Erythematosus Research
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- Diverticular Disease and Complications
- Genetic factors in colorectal cancer
- Tuberculosis Research and Epidemiology
- Pharmacological Effects of Natural Compounds
- Autoimmune and Inflammatory Disorders Research
- Stoma care and complications
- Colorectal and Anal Carcinomas
- Pneumocystis jirovecii pneumonia detection and treatment
- Biosimilars and Bioanalytical Methods
Centre Hospitalier Universitaire de Liège
2015-2025
University of Liège
2018-2025
Inserm
2025
Agroécologie
2025
INTRODUCTION: Patients with ulcerative colitis (UC) receiving immunosuppressive drugs are at substantial risk of colectomy. We aimed to assess the postoperative complications tofacitinib exposure before colectomy in comparison biologics. METHODS: A multicenter, retrospective, observational study was conducted patients UC who underwent total for medically refractory disease, exposed or a biologic surgery. Primary outcome occurrence any complication within 30 (early) and 90 (late) days after...
Abstract Background and Aim Mesenchymal stem cells [MSCs] have anti-inflammatory anti-fibrotic properties could be a potential therapy for Crohn’s disease [CD] strictures. In this phase I–II pilot trial, we assessed safety efficacy of local MSC injection to treat CD Methods patients with short [less than 5 cm in length] non-passable stricture accessible by ileocolonoscopy were included. Allogenic bone-marrow derived MSCs injected the four quadrants stricture. Adverse events clinical scores...
Abstract Background and Aims Data regarding the effectiveness safety of Janus kinase [JAK] inhibitors sphingosine-1-phosphate [S1P] receptor modulators in antibiotic refractory chronic pouchitis [CARP] are lacking. Methods This ECCO-CONFER project retrospectively collected data for JAK inhibitor or S1P modulator treatments CARP with at least 3 months follow-up. The outcomes included corticosteroid- antibiotic-free clinical response remission 12 months, trends modified disease activity index...
Abstract Background Crohn’s disease (CD) is a chronic and progressive condition with growing global prevalence, leading to potential bowel damage disability. Data on the clinical presentation, outcomes, treatment options in newly diagnosed CD patients Europe current era are essential guide physicians. The aim describe characteristics of contemporary European cohort recently patients. Methods Crohn's Disease Cohort (CROCO) an ongoing, multicenter, prospective study within last 12 months,...
Abstract Background Perianal fistulae affects 30-34% of patients with Crohn’s Disease (CD)[1]. Scarce evidences are available on the perianal fistula pathophysiology. Bone marrow-derived Mesenchymal Stem Cells (bmMSCs) local injections have been found safe and efficient for 50% CD included in a previous prospective monocentric study[2]. The present study aims at identifying potential proteins associated closure following bmMSCs injection, using biological material collected during tract...
Abstract Background Inflammatory bowel disease (IBD) patients with Clostridiodes difficile Infection (CDI) are at increased risk of exacerbations, therapy escalation, colectomy, and mortality. Data on fidaxomicin use in IBD CDI very limited. We aimed to assess the effectiveness safety for its impact outcomes a large retrospective multicenter cohort study. Methods Adult ulcerative colitis (UC) or Crohn’s (CD) episode (positive toxin enzyme immunoassay polymerase chain reaction toxigenic C....
Abstract Background The therapeutic options for Inflammatory Bowel Disease (IBD) have expanded with the introduction of JAK inhibitors. However, real-world data on upadacitinib (UPA) in patients moderate to severe Crohn’s disease (CD) are scarce. Our aim was assess long-term effectiveness and safety UPA multi-refractory Belgian patients. Methods Data from all active CD initiating between September 2022 January 2024 were retrospectively collected 17 centres. Effectiveness endpoints evaluated...
Abstract Background Crohn’s disease (CD) complicated with intra-abdominal abscess often requires surgical intervention. Image guided percutaneous drainage (PD) can help to avoid interventions, however there is limited evidence on the optimal management after PD. Our study aimed analyze long-term outcomes of CD Methods In this multicenter, multinational retrospective trial penetrating patients simplex were enrolled and followed. Baseline was defined as day first detection abdominal abscess,...
Abstract Background JAK inhibitors (JAKi) can induce and maintain remission in inflammatory bowel disease (IBD). Around 5% of IBD patients develop primary sclerosing cholangitis (PSC). Given the potential involvement JAK/STAT signaling PSC pathogenesis, JAKi may have a role modulating IBD-related PSC. We aim to explore course IBD-PSC on for IBD. Methods Following call-for-cases via ECCO CONFER (Round 10), we retrospectively collected baseline outcome data both IBD, before after treatment,...
Abstract Background Despite its interest for the development of personalised medicine, pathophysiological distinctions between ileal and colonic Crohn’s disease (CD) have been poorly characterised. This study aims to search immunological differences CD. Methods We reanalysed our proteomic dataset1 extract non-exploited information. Using mass spectrometry-based proteomics, we previously compared proteome ulcer edges adjacent normal mucosa (paired design) in ileum (n=16 biopsies) colon 16 CD...
Abstract Background Crohn’s disease (CD) often results in progressive bowel damage and disability. Disability has been proposed as an endpoint for disease-modification trials by the SPIRIT-IOIBD1 consensus, though data on evolution of IBD-Disability Index (IBD-DI) over time remain limited. Methods The Disease Cohort (CROCO) is a prospective, ongoing study newly diagnosed CD patients (within 12 months diagnosis), assessing changes was measured using validated (IBD-DI), which includes 14...
Abstract Background Increased permeability, mucosal barrier and epithelial anomalies (crypt distortion, wider crypt lumen, gaps) as well altered tight junctions have been described in active ulcerative colitis (UC) Crohn’s Disease (CD). Probe based Confocal laser endomicroscopy (pCLE) is able to monitor vivo1. This study aimed at comparing the proteomic profiles of colonic epithelium associated with pCLE UC, CD non-IBD subjects. Methods Biopsies were collected IBDs endoscopic remission...
Abstract Background Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) with diffuse colonic mucosal inflammation. Fibrosis has been observed in the submucosa and muscularis mucosae even without active inflammation2, yet remains underexplored UC. No anti-fibrotic treatments currently exist for IBD4. At epithelial level, IBD-related endoplasmic reticulum stress (ERS) inflammation upregulate ER chaperones like AGR2, which, when secreted extracellularly (eAGR2), can induce...
Abstract Background Very few data exist on the use of a second JAK inhibitor (JAKi) in patients with ulcerative colitis (UC), already exposed to first line JAKi. The aim this study was evaluate efficacy and safety JAKi UC. Methods We conducted an ambispective observational multicenter 28 Belgian French centers. All refractory UC, previously first-line subsequently receiving another JAKi, were included between July 2019 September 2024. primary endpoint corticosteroid-free clinical remission...
Abstract Background Crohn’s disease (CD) progression manifests as bowel damage (BD) and disability; prevention of both is a long-term treatment target in CD. However, the longitudinal characterization BD disability early CD patients remains limited. Methods The Crohn´s Disease Cohort (CROCO) multicentre, European cohort study recently diagnosed (<12 months following diagnosis) designed to prospectively characterize disability. At one year diagnosis (Y1), was evaluated using Lemann...
Abstract Background Colitis-associated cancer (CAC) is a distinct entity from sporadic colorectal (CRC)1. Previous studies have demonstrated that Solute Carrier Family 12 Member 2 (SLC12A2/NKCC1), Na-K-Cl cotransporter, tissue marker able to discriminate dysplasia inflammatory and normal tissues2. NKCC1 overexpressed in both pre-tumoral tumoral lesions of CAC CRC. It located at the cell membrane cytoplasm mainly expressed fluid-secreting cells. In IBD, mutations cause defects mucus secretion...
Abstract Background The best maintenance therapy after a steroid-responsive acute severe ulcerative colitis (ASUC) episode remains poorly studied and is not addressed in current guidelines. We aimed to compare the impact of different treatment strategies following hospitalization for ASUC. Methods Multicentric, multinational, retrospective cohort study including patients hospitalized with ASUC, between 2010-2021, who responded intravenous steroids (Oxford Criteria). Patients were categorized...
Abstract Background Anterior Gradient 2 (AGR2) is an endoplasmic reticulum (ER) resident protein involved in folding, predominantly expressed mucin-secreting epithelial cells. Under stress, AGR2 secreted into the extracellular milieu (eAGR2), where it disrupts integrity, attracts monocytes, and activates fibroblasts. We explored relationship between tissue expression IBD patients efficacy of a neutralizing anti-eAGR2 antibody (TH-009) murine models colonic inflammation fibrosis Methods was...
ABSTRACT Background and aims Probe‐based confocal endomicroscopy (pCLE) allows real‐time microscopic visualization of the intestinal mucosa surface layers. Despite remission achieved through anti‐tumor necrosis factor or vedolizumab therapy, anomalies in epithelial barrier are observed inflammatory bowel disease (IBD) patients. Our study aimed to assess these abnormalities non‐IBD individuals compare them with IBD patients endoscopic identify associated factors. Methods The involved 84...